Serum Galanin Concentration is Increased in Subjects with Impaired Glucose Tolerance. 2017

Zhenwen Zhang, and Penghua Fang, and Mei Yu, and Yan Wang, and Yin Li, and Mingyi Shi, and Ping Bo, and Xuewen Gu, and Yan Zhu
Department of Endocrinology, Clinical Medical College, Yangzhou University, Yangzhou, China.

OBJECTIVE Although extensive data have shown that galanin can regulate the food intake and glucose metabolism of animals, little is known regarding the galanin concentration in patients with impaired glucose tolerance (IGT). Therefore, the aims of this study were to investigate whether serum galanin levels and other metabolic parameters are changed in patients with IGT compared with controls with normal glucose tolerance (NGT). METHODS Data regarding serum galanin levels and relative metabolic parameters were collected in 12 patients with IGT and 12 healthy patients with NGT. RESULTS At 1 hour and 2 hours after dinner, serum galanin, insulin and glucose levels were significantly higher in patients with IGT than in controls with NGT. Additionally, the body weights of patients with IGT was higher than those of the controls. Furthermore, a negative correlation was found between galanin levels and 1-hour glucose concentrations (r=-0.580; p=0.048) in patients with IGT. CONCLUSIONS The higher serum galanin levels as well as the negative correlation between galanin levels and 1-hour glucose content in patients with IGT may result from the interaction between insulin and galanin in differing conditions, suggesting that the galanin level may be used as a potential biomarker for the prediction of IGT in clinical settings.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults
D018149 Glucose Intolerance A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION. Impaired Glucose Tolerance,Glucose Intolerances,Glucose Tolerance, Impaired,Glucose Tolerances, Impaired,Impaired Glucose Tolerances,Intolerance, Glucose,Intolerances, Glucose,Tolerance, Impaired Glucose,Tolerances, Impaired Glucose

Related Publications

Zhenwen Zhang, and Penghua Fang, and Mei Yu, and Yan Wang, and Yin Li, and Mingyi Shi, and Ping Bo, and Xuewen Gu, and Yan Zhu
October 1989, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
Zhenwen Zhang, and Penghua Fang, and Mei Yu, and Yan Wang, and Yin Li, and Mingyi Shi, and Ping Bo, and Xuewen Gu, and Yan Zhu
May 1988, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
Zhenwen Zhang, and Penghua Fang, and Mei Yu, and Yan Wang, and Yin Li, and Mingyi Shi, and Ping Bo, and Xuewen Gu, and Yan Zhu
July 1995, Diabetes care,
Zhenwen Zhang, and Penghua Fang, and Mei Yu, and Yan Wang, and Yin Li, and Mingyi Shi, and Ping Bo, and Xuewen Gu, and Yan Zhu
July 2000, The British journal of nutrition,
Zhenwen Zhang, and Penghua Fang, and Mei Yu, and Yan Wang, and Yin Li, and Mingyi Shi, and Ping Bo, and Xuewen Gu, and Yan Zhu
June 2020, Endocrinology and metabolism (Seoul, Korea),
Zhenwen Zhang, and Penghua Fang, and Mei Yu, and Yan Wang, and Yin Li, and Mingyi Shi, and Ping Bo, and Xuewen Gu, and Yan Zhu
January 2002, Renal failure,
Zhenwen Zhang, and Penghua Fang, and Mei Yu, and Yan Wang, and Yin Li, and Mingyi Shi, and Ping Bo, and Xuewen Gu, and Yan Zhu
February 2007, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme,
Zhenwen Zhang, and Penghua Fang, and Mei Yu, and Yan Wang, and Yin Li, and Mingyi Shi, and Ping Bo, and Xuewen Gu, and Yan Zhu
November 2013, International journal of cardiology,
Zhenwen Zhang, and Penghua Fang, and Mei Yu, and Yan Wang, and Yin Li, and Mingyi Shi, and Ping Bo, and Xuewen Gu, and Yan Zhu
May 1993, Diabetic medicine : a journal of the British Diabetic Association,
Zhenwen Zhang, and Penghua Fang, and Mei Yu, and Yan Wang, and Yin Li, and Mingyi Shi, and Ping Bo, and Xuewen Gu, and Yan Zhu
September 1987, The Indian journal of medical research,
Copied contents to your clipboard!